Hypersensitivity Reactions

The immune system is a remarkably powerful defense network, yet its capacity for destruction can turn inward, causing tissue damage when immune responses are misdirected or exaggerated. The study of hypersensitivity reactions arose from early observations that immunization could, paradoxically, sensitize an organism to subsequent injury rather than protection. Understanding the historical trajectory of this field illuminates why we classify immune-mediated damage into four distinct types, each with unique mechanisms, clinical presentations, and therapeutic implications that are central to boards-level immunology.

The central question that the Gell and Coombs classification addresses is deceptively simple: when the immune system damages self-tissue, which effector mechanism is responsible? Answering this question is clinically essential because each type of hypersensitivity demands a different diagnostic approach and therapeutic strategy, from epinephrine in anaphylaxis to plasmapheresis in antibody-mediated disease to immunosuppression in delayed-type hypersensitivity.

Hypersensitivity reactions represent immunologic responses that are qualitatively normal but quantitatively excessive or misdirected, leading to tissue injury. The Gell and Coombs classification system organizes these reactions based on the immune effector mechanism responsible for tissue damage. Types I, II, and III are antibody-mediated (humoral), while Type IV is cell-mediated. Each type involves a sensitization phase (first exposure to antigen) followed by an effector phase (re-exposure causing tissue damage). A critical principle is that the same antigen can trigger different hypersensitivity types depending on its location, form, and the host's immune profile.

The diagram above organizes the four hypersensitivity types into a two-by-two layout that emphasizes the fundamental dichotomy between antibody-mediated (Types I–III) and cell-mediated (Type IV) damage. In Type I, IgE bound to mast cell Fcε receptors triggers immediate degranulation upon crosslinking by antigen, releasing histamine and leukotrienes. In Type II, IgG or IgM antibodies target fixed antigens on cell surfaces or basement membranes, resulting in complement activation, opsonization, or ADCC. Type III involves soluble immune complexes that deposit in tissues and recruit neutrophils through complement fragments C3a and C5a. Type IV is uniquely antibody-independent: CD4⁺ T_H1 cells release cytokines (IFN-γ, TNF) that activate macrophages, while CD8⁺ cytotoxic T lymphocytes directly kill target cells via perforin and granzymes.

Type I — IgE-Mediated Immediate Hypersensitivity

Type I hypersensitivity proceeds in two phases. During sensitization, antigen-presenting cells process allergens and present peptides to CD4⁺ T_H2 cells, which secrete IL-4 and IL-13 to drive B-cell class switching to IgE. The IgE then binds to high-affinity FcεRI receptors on mast cells and basophils, priming them for subsequent activation. Upon re-exposure, multivalent antigen crosslinks surface-bound IgE molecules, triggering receptor aggregation and intracellular signaling cascades that culminate in degranulation.

The early phase (within minutes) involves release of preformed mediators — histamine (vasodilation, increased vascular permeability, bronchoconstriction), tryptase (a clinical marker), heparin, and TNF-α. The late phase (4–8 hours) involves de novo synthesis of arachidonic acid metabolites (leukotrienes C₄, D₄, E₄ via lipoxygenase; prostaglandin D₂ via cyclooxygenase) and cytokines (IL-4, IL-5, IL-13) that recruit eosinophils and perpetuate inflammation. Serum tryptase elevation confirms mast cell degranulation and is a useful diagnostic marker for anaphylaxis.

Type II — Antibody-Mediated Cytotoxic Hypersensitivity

In Type II reactions, IgG or IgM antibodies are directed against antigens that are fixed on cell surfaces (such as blood group antigens on erythrocytes) or within the extracellular matrix (such as type IV collagen in the glomerular basement membrane in Goodpasture syndrome). Three effector mechanisms cause damage. First, complement activation via the classical pathway generates the membrane attack complex (C5b-9), causing direct cell lysis, and produces anaphylatoxins (C3a, C5a) that recruit inflammatory cells. Second, opsonization with C3b and IgG Fc fragments targets cells for phagocytosis by macrophages. Third, antibody-dependent cellular cytotoxicity (ADCC) involves NK cells recognizing IgG-coated targets through CD16 (FcγRIII).

Type III — Immune Complex–Mediated Hypersensitivity

Type III hypersensitivity occurs when antigen-antibody (primarily IgG) complexes form in the circulation and deposit in tissues where blood is filtered or turbulent, particularly renal glomeruli, joint synovium, and small vessel walls. The deposited complexes activate complement through the classical pathway, generating C3a and C5a (anaphylatoxins) that recruit neutrophils. These neutrophils release lysosomal enzymes and reactive oxygen species, causing local tissue destruction. Immune complex size matters: small complexes remain soluble and are cleared by the reticuloendothelial system, while intermediate-sized complexes are most pathogenic because they evade efficient clearance yet are large enough to deposit in tissues. The Arthus reaction is a localized Type III response at an injection site, while serum sickness represents a systemic form, classically presenting 7–10 days after exposure with fever, urticaria, arthralgias, proteinuria, and lymphadenopathy.

Type IV — Delayed-Type (Cell-Mediated) Hypersensitivity

Type IV is the only hypersensitivity type that does not involve antibodies. Instead, sensitized T cells mediate tissue damage. In the classic delayed-type hypersensitivity (DTH) reaction, antigen is processed by macrophages and presented via MHC class II to CD4⁺ T_H1 cells, which release IFN-γ and TNF-α. IFN-γ is the most important macrophage-activating cytokine, enhancing their microbicidal capacity and driving granuloma formation when antigen persists (as in tuberculosis and sarcoidosis). In the cytotoxic subtype, CD8⁺ T cells recognize antigen presented on MHC class I and kill target cells via perforin/granzyme pathways and Fas-FasL interactions. Contact dermatitis (e.g., poison ivy, nickel allergy) involves hapten-modified self-proteins presented to T cells in skin-draining lymph nodes, with clinical manifestation at 48–72 hours after re-exposure.

A critical distinction for boards examinations is the immunofluorescence (IF) pattern. Type II reactions classically show a linear IF pattern because antibodies bind uniformly to antigens distributed along basement membranes (as seen in Goodpasture syndrome targeting the GBM). In contrast, Type III reactions produce a granular ("lumpy-bumpy") IF pattern because immune complexes deposit in an irregular, patchy fashion. This distinction is commonly tested in the context of renal biopsies showing glomerulonephritis.

The USMLE frequently tests hypersensitivity reactions through clinical vignettes that require you to identify the reaction type based on temporal relationships, pathologic findings, and clinical features. The following worked example demonstrates a systematic approach to dissecting such a question.

Hypersensitivity reactions form the mechanistic foundation for understanding autoimmune diseases, transplant immunology, and targeted immunopharmacology. Each hypersensitivity type has specific pharmacologic interventions that map directly to the effector mechanism involved, and understanding these connections is essential for Step 1 integration questions that bridge immunology with pharmacology.

Looking forward, advanced topics in immunology build directly on the hypersensitivity framework. The concept of immune tolerance (central and peripheral) represents the mechanisms that normally prevent hypersensitivity reactions, and their failure leads to autoimmunity. The emerging field of checkpoint inhibitor therapy in oncology essentially unleashes Type IV hypersensitivity against tumors but can cause immune-related adverse events (irAEs) that recapitulate classic hypersensitivity pathology in virtually any organ system. Additionally, graft-versus-host disease (GVHD) after allogeneic stem cell transplant represents donor T-cell–mediated (Type IV) attack on recipient tissues, underscoring the clinical relevance of these mechanisms beyond classical allergic disease.